Followers | 72 |
Posts | 4223 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Wednesday, November 16, 2022 12:20:42 PM
https://academic.oup.com/ijnp/advance-article/doi/10.1093/ijnp/pyac075/6808755?login=false
Anna M Becker, Aaron Klaiber, Friederike Holze, Ioanna Istampoulouoglou, Urs Duthaler, Nimmy Varghese, Anne Eckert, Matthias E Liechti
International Journal of Neuropsychopharmacology, pyac075, https://doi.org/10.1093/ijnp/pyac075
Published: 07 November 2022 Article history
Background
Lysergic acid diethylamide (LSD) is currently being investigated in psychedelic-assisted therapy. LSD has a long duration of acute action of 8-11 h. It produces its acute psychedelic effects via stimulation of the serotonin 5-hydroxytryptamine-2A (HT2A) receptor. Administration of the 5-HT2A antagonist ketanserin before LSD almost fully blocks the acute subjective response to LSD. However, unclear is whether ketanserin can also reverse the effects of LSD when administered after LSD.
Methods
We used a double-blind, randomized, placebo-controlled, crossover design in 24 healthy subjects who underwent two 14-h sessions and received ketanserin (40 mg p.o.) or placebo 1 h after LSD (100 µg p.o.). Outcome measures included subjective effects, autonomic effects, acute adverse effects, plasma brain-derived neurotrophic factor (BDNF) levels, and pharmacokinetics up to 12 h.
Results
Ketanserin reversed the acute response to LSD, thereby significantly reducing the duration of subjective effects from 8.5 h with placebo to 3.5 h. Ketanserin also reversed LSD-induced alterations of mind, including visual and acoustic alterations and ego dissolution. Ketanserin reduced adverse cardiovascular effects and mydriasis that were associated with LSD but had no effects on elevations of BDNF levels. Ketanserin did not alter the pharmacokinetics of LSD.
Conclusions
These findings are consistent with an interaction between ketanserin and LSD and the view that LSD produces its psychedelic effects only when occupying 5-HT2A receptors. Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy.
LSD, ketanserin, interaction, subjective effects, pharmacokinetics
Issue Section: Regular Research Article
Recent MNMD News
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:15:11 PM
- MindMed Reports 2023 Financial Results and Business Updates • Business Wire • 02/28/2024 12:05:00 PM
- MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update • Business Wire • 02/22/2024 12:00:00 PM
- MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference • Business Wire • 02/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:24 PM
- MindMed Announces Business Update and Anticipated Milestones for 2024 • Business Wire • 01/08/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 09:59:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 09:50:28 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM